Phase 1Status unknown
CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers
A Phase I Study to Evaluate the Safety, Tolerance and Efficacy of CRTE7A2-01 TCR-T Cell for HPV16 Positive Advanced Cervical, Anal, or Head and Neck Cancers
- Sponsor
- Corregene Biotechnology Co., Ltd (Industry)
- Enrollment
- 12 planned
- Conditions
- Cervical Cancer; Anal Cancer; Head and Neck Cancers
- Interventions
- Fludarabine + Cyclophosphamide; Interleukin-2; CRTE7A2-01 TCR-T Cell
- Ages
- adults, older adults
- Registry
- NCT05122221
Full record on ClinicalTrials.gov
From the registry
A single center, open, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of CRTE7A2-01 TCR-T cell for HPV16 positive advanced cervical, anal, or head and neck cancers. The study will determine MTD of CRTE7A2-01 TCR-T cell injection, as well as investigate RP2D.
Primary outcomes
- MTD
- DLT
- RP2D
- Incidence of treatment related AEs, AEs of special interest and serious adverse events (SAEs).
History
Study completion
Primary completion
Started
Last registry update
Registered